CSIMarket


Kinnate Biopharma Inc   (KNTE)
Other Ticker:  
 


 

Kinnate Biopharma Inc

KNTE's Financial Statements and Analysis



Kinnate Biopharma Inc narrowed third quarter of 2023 net loss per share of $-0.65 compare to net loss per share of $-0.70 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.68 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.65 $  0 Mill
$+0.05     Unch.    



Kinnate Biopharma Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Kinnate Biopharma Inc is

More on KNTE's Income Statement



Kinnate Biopharma Inc 's in thethird quarter of 2023 recorded net loss of $-30.733 million, an improvement compare to net loss of $-30.737 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-31.918 million realized in previous quarter.

More on KNTE's Growth

Kinnate Biopharma Inc Inventories
KNTE's Cash flow In the third quarter of 2023 company's net cash flow was $17 million


Kinnate Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Kinnate Biopharma Inc payed $ -2.26 cash per share, on a free-cash flow basis .

Book value fell by -13.56 % sequentially to $3.66 per share, -20.77% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.66 per share from $ 4.24.

Company issued 0.44 million shares or 0.94 % in Sep 30 2023.


More on KNTE's Dividends

 Market Capitalization (Millions) 120
 Shares Outstanding (Millions) 47
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Kinnate Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Kinnate Biopharma Inc had negative $ -2.26 cash flow per share, on a free-cash flow basis .

Book value fell by -13.56 % sequentially to $3.66 per share, -20.77% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.66 per share from $ 4.24.

Company issued 0.44 million shares or 0.94 % in Sep 30 2023.


More on KNTE's Balance Sheets

 Market Capitalization (Millions) 120
 Shares Outstanding (Millions) 47
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Kinnate Biopharma Inc Earnings

Kinnate Biopharma Inc. Surprises Investors with Unexpected Operating Shortfall in Q3 2023



The Major Pharmaceutical Preparations industry is currently abuzz with discussions surrounding Kinnate Biopharma Inc's recent financial performance for the third quarter of 2023. Although the company reported an operating shortfall of $-33.089 million and no revenue for the quarter, shareholders remain optimistic about the future due to an anticipated business strategy. This article aims to provide insightful context about Kinnate Biopharma Inc's market and stock performance.
Challenging Third Quarter Results
During the July to September 30 2023 quarter, Kinnate Biopharma Inc faced a significant operating shortfall of $-33.089 million, which raises concerns about the company's financial sta...

Kinnate Biopharma Inc Faces Mounting Concerns as Operating Deficit Soars to $34.135 Million in Second Quarter of 2023



Kinnate Biopharma Inc, a lesser-known player in the Major Pharmaceutical Preparations industry, has recently announced its operating deficit for the second quarter of 2023. With a staggering $-34.135 million deficit, the company's financial situation raises concerns among investors and industry analysts. Furthermore, the company's net loss of $-31.918 million, which has expanded from the previous year, adds to the bearish sentiment surrounding Kinnate Biopharma Inc. As the company approaches its next financial results announcement on August 10, 2023, it becomes crucial to analyze the factors contributing to its declining performance.
Operational Deficit Expansion:
Comparing the operating de...

Kinnate Biopharma Inc. Reports Operating Loss in Q1 2023: Company Strives to Overcome Challenges in Cancer Precision Medicine Development

Kinnate Biopharma Inc. is a biopharmaceutical c...


Date modified: 2023-11-12T10:02:19+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com